Genmab (BST:GE91) - Cotización, noticias y análisis

Resumen de acción GE91

Genmab A/S desarrolla terapias de anticuerpos para el tratamiento del cáncer y otras enfermedades, principalmente en Dinamarca. Saber más

Análisis fundamental de GE91
Puntuación del snowflake
Valoración	5/6
Crecimiento futuro	4/6
Rendimiento pasado	4/6
Salud financiera	6/6
Dividendos	0/6

Recompensas

Cotiza un 84.8% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 23.73%

Los beneficios aumentaron un 12.9% el pasado año

Cotiza a buen valor en comparación con empresas similares e industria

Análisis de riesgos

No se han detectado riesgos en GE91 a partir de nuestros controles de riesgos.

Competidores de Genmab A/S

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€818.4m

Sartorius

XTRA:SRT3

€13.4b

SCHOTT Pharma KGaA

XTRA:1SXP

€4.0b

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Genmab
Precios históricos de las acciones
Precio actual de la acción	DKK 19.60
Máximo en las últimas 52 semanas	DKK 30.20
Mínimo de 52 semanas	DKK 19.60
Beta	0.86
1Cambio en 1 mes	-9.26%
Variación en 3 meses	-17.65%
Cambio de 1 año	-34.67%
3Variación en 3 años	-46.45%
Variación en 5 años	-6.06%
Variación desde la OPV	20.82%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	GE91	DE Biotechs	Mercado DE
7D	-7.5%	-1.0%	-0.5%
1Y	-34.7%	-16.7%	8.3%

Rentabilidad vs. Industria: Los resultados de GE91 fueron inferiores a los de la industria German Biotechs, que obtuvo un rendimiento del -16.7% el año pasado.

Rentabilidad vs. Mercado: GE91 obtuvo unos resultados inferiores a los del mercado German, que fueron del 8.3% el año pasado.

Volatilidad de los precios

Is GE91's price volatile compared to industry and market?
GE91 volatility
GE91 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.0%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: No se dispone de datos.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de GE91 en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1999	2,635	Jan G.J. de Winkel	www.genmab.com

Genmab A/S desarrolla anticuerpos terapéuticos para el tratamiento del cáncer y otras enfermedades, principalmente en Dinamarca. La empresa comercializa DARZALEX, un anticuerpo monoclonal humano para el tratamiento de pacientes con mieloma múltiple (MM); teprotumumab para el tratamiento de la enfermedad ocular tiroidea; y Amivantamab para el cáncer gástrico o esofágico avanzado o metastásico y el CPNM. Sus productos incluyen daratumumab para tratar MM, cánceres de la sangre no MM y amiloidosis AL; GEN1047; tisotumab vedotin para tratar cánceres de cuello uterino, ovario y sólidos; DuoBody-PD-L1x4-1BB, y DuoBody-CD40x4-1BB para tratar tumores sólidos; Epcoritamab para el linfoma difuso de células B grandes y la leucemia linfocítica crónica en recaída o refractarios; y HexaBody-CD38 y GEN3017 para el tratamiento de neoplasias hematológicas.

Resumen de fundamentos de Genmab A/S

¿Cómo se comparan los beneficios e ingresos de Genmab con su capitalización de mercado?
Estadísticas fundamentales de GE91
Capitalización bursátil	€12.35b
Beneficios(TTM)	€630.34m
Ingresos (TTM)	€2.66b

19.6x

Ratio precio-beneficio (PE)

4.6x

Ratio precio-ventas (PS)

¿Está GE91 sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de GE91
Ingresos	DKK 19.84b
Coste de los ingresos	DKK 774.00m
Beneficio bruto	DKK 19.07b
Otros gastos	DKK 14.37b
Beneficios	DKK 4.70b

Últimos beneficios comunicados

Sep 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	74.03
Margen bruto	96.10%
Margen de beneficio neto	23.69%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado GE91 a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción GE91

Recompensas

Análisis de riesgos

Competidores de Genmab A/S

XTRA:BIO3

€1.4b

XTRA:FYB

€818.4m

XTRA:SRT3

€13.4b

XTRA:1SXP

€4.0b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha (FRa)-Targeted, Topo1 Antibody-Drug Conjugate

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Executive Changes

Genmab A/S Takes Full Control of Acasunlimab Development Program

Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Recent updates

Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha (FRa)-Targeted, Topo1 Antibody-Drug Conjugate

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Executive Changes

Genmab A/S Takes Full Control of Acasunlimab Development Program

Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S Announces Executive Changes

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Revises Earnings Guidance for the Year 2023

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

Genmab A/S Announces Submission of Japan New Drug Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Genmab A/S Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Genmab A/S Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (Bla) for Epcoritamab (Duobody®-Cd3xcd20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (Lbcl)

Genmab Provides Earnings Guidance for Year 2022

Genmab A/S Submits Biologics License Application to the U.S. Food and Drug Administration

Genmab A/S Revises Earnings Guidance for the Year 2022

Genmab A/S Submits Biologics License Application to U.S. Food and Drug Administration for Epcoritamab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

Genmab A/S and Seagen Inc. Present Data from Tisotumab Vedotin (TIVDAK) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

Genmab A/S Revises Earnings Guidance for 2022

AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Genmab A/S Elects Elizabeth O’Farrell to the Board of Directors

Genmab A/S Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People Officer

Genmab A/S Provides Earnings Guidance for the Year 2022

Genmab A/S Provides Earnings Guidance for the Year 2022

Genmab A/S Announces Janssen Received Conditional European Marketing Authorization for RYBREVANT

U.S. Food and Drug Administration Grants Approval to TIVDAK

Seagen Inc. and Genmab A/S Announce FDA Accelerated Approval for TIVDAK™ (Tisotumab Vedotin-Tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer

Genmab A/S Announces the Lancet Published the Results of FIH Trial

Genmab A/S Improves Revenue Guidance for the Full Year of Fiscal 2021

Genmab A/S Announces That Janssen Has Received European Marketing Authorizations for Darzalex® (Daratumumab) Subcutaneous Formulation, Including for the Treatment of Patients with Newly Diagnosed Light-Chain (Al) Amyloidosis

Genmab Announces Janssen Received Positive CHMP Opinion Recommending DARZALEX (daratumumab) Subcutaneous (SC) Formulation for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis

Genmab Announces Abstracts Evaluating Products in Pipeline, Portfolio to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress

Genmab A/S Reaffirms Financial Guidance for Fiscal 2021

Genmab A/S Provides Revenue Guidance for the Full Year of Fiscal 2021

Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental Medicines